ES2616049T3 - Mejora de la función renal con composiciones que contienen quercetina - Google Patents

Mejora de la función renal con composiciones que contienen quercetina Download PDF

Info

Publication number
ES2616049T3
ES2616049T3 ES09795103.2T ES09795103T ES2616049T3 ES 2616049 T3 ES2616049 T3 ES 2616049T3 ES 09795103 T ES09795103 T ES 09795103T ES 2616049 T3 ES2616049 T3 ES 2616049T3
Authority
ES
Spain
Prior art keywords
improvement
compositions containing
renal function
containing quercetin
quercetin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09795103.2T
Other languages
English (en)
Inventor
Thomas Christian Lines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quercegen Pharmaceuticals LLC
Original Assignee
Quercegen Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quercegen Pharmaceuticals LLC filed Critical Quercegen Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2616049T3 publication Critical patent/ES2616049T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición que contiene quercetina, vitamina C y vitamina B3, para usar para mejora la función renal en un sujeto.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES09795103.2T 2008-07-09 2009-07-08 Mejora de la función renal con composiciones que contienen quercetina Active ES2616049T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US169869 1988-03-17
US12/169,869 US8680053B2 (en) 2008-07-09 2008-07-09 Improving renal function with quercetin-containing compositions
PCT/US2009/049902 WO2010006026A2 (en) 2008-07-09 2009-07-08 Improving renal function with quercetin-containing compositions

Publications (1)

Publication Number Publication Date
ES2616049T3 true ES2616049T3 (es) 2017-06-09

Family

ID=41505712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09795103.2T Active ES2616049T3 (es) 2008-07-09 2009-07-08 Mejora de la función renal con composiciones que contienen quercetina

Country Status (8)

Country Link
US (2) US8680053B2 (es)
EP (1) EP2310007B1 (es)
CN (1) CN102088970B (es)
AU (1) AU2009268637A1 (es)
CA (1) CA2730065C (es)
ES (1) ES2616049T3 (es)
NZ (1) NZ590762A (es)
WO (1) WO2010006026A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054743A2 (en) * 2010-10-20 2012-04-26 Yongquan Xue Taste modifying compositions
CN102218049B (zh) * 2011-05-06 2013-03-13 天津艾赛博生物技术有限公司 抗衰老的药物或保健食品组合物及用途
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
US9517249B2 (en) 2012-11-26 2016-12-13 Access Business Group International Llc Antioxidant dietary supplement and related method
CN104997129A (zh) * 2015-06-17 2015-10-28 哈尔滨松根堂生物科技有限公司 一种富含活性因子的高效复合食品添加剂及应用
SE542106C2 (en) * 2016-08-26 2020-02-25 Atif M Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
PH12018000227B1 (en) * 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
CA3121235A1 (en) 2018-11-30 2020-06-04 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients
CN116270592A (zh) * 2022-10-31 2023-06-23 王彬 一种新型抑制外泌体释放的药物及其用途
WO2024101209A1 (ja) * 2022-11-07 2024-05-16 サントリーホールディングス株式会社 ケルセチン又はその配糖体を含有する腎機能の低下抑制又は改善用組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310194D0 (en) * 1993-05-18 1993-06-30 Millenium Bioligix Inc Assessment of osteoclast activity
AU689036B2 (en) 1995-05-10 1998-03-19 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
CN1132643A (zh) 1995-12-01 1996-10-09 冯学祯 一种用于治疗肝胆系统疾病的药
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6995166B1 (en) * 2000-09-27 2006-02-07 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiencies in renal patients
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20040126461A1 (en) * 2002-10-23 2004-07-01 Lines Thomas Christian Composition for enhancing physical performance
US6821536B2 (en) * 2002-11-22 2004-11-23 Quercegen Holdings Llc Antioxidative compositions
CN100361599C (zh) 2002-10-23 2008-01-16 克尔塞根控股有限公司 抗氧化组合物
US20040137080A1 (en) * 2003-01-13 2004-07-15 Cremisi Henry D. Multivitamin regimen for renal patients
CN100409893C (zh) 2006-05-30 2008-08-13 昆明禾润药物开发有限公司 治疗肾功能衰竭的药物及其制备方法
US7745486B2 (en) 2006-07-17 2010-06-29 Quercegen Pharma Llc Quercetin-containing compositions
CN101032619B (zh) 2007-02-02 2010-05-19 贾聚宝 一种治疗原发性高血压的口服药液及其制备方法
CN100560125C (zh) 2007-08-20 2009-11-18 山西医科大学第二医院 一种治疗心脑血管疾病的药物及其制备方法
CN101199834A (zh) 2007-12-21 2008-06-18 北京中科雍和医药技术有限公司 一种治疗肺癌的中药组合物及其制备方法
DE102009015917A1 (de) 2009-03-13 2010-10-14 Lang, Florian, Prof. Dr. Mittel zur Hemmung und/oder Prophylaxe von Eryptose

Also Published As

Publication number Publication date
EP2310007A4 (en) 2014-01-15
CN102088970B (zh) 2013-06-26
CN102088970A (zh) 2011-06-08
US20140206695A1 (en) 2014-07-24
US8680053B2 (en) 2014-03-25
AU2009268637A1 (en) 2010-01-14
WO2010006026A2 (en) 2010-01-14
EP2310007A2 (en) 2011-04-20
US20100010005A1 (en) 2010-01-14
EP2310007B1 (en) 2016-11-16
CA2730065C (en) 2017-07-04
NZ590762A (en) 2012-09-28
CA2730065A1 (en) 2010-01-14
WO2010006026A3 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
ES2616049T3 (es) Mejora de la función renal con composiciones que contienen quercetina
ES2637421T3 (es) Composiciones tópicas que comprenden variantes de pliegue-OB
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
ES2571041T3 (es) Composiciones antimicrobianas
CR20120463A (es) Formulaciones de aceite que comprenden compuestos ciclopropeno
ES2508165T3 (es) Lactoferrina y sustancia blanca
CL2011000462A1 (es) Composicion de aceite que contiene aceite y caldo, en que la proporcion de aceite a caldo varia desde 1:1 hasta 1:3; metodo de preparacion de dicha composicion; uso de dicha composicion; y metodo para la preparacion de productos a base de carne que contienen aceite.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
ES2613400T3 (es) Método para mejorar la fagocitosis de células que exponen fosfatidilserina
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
EA201490178A1 (ru) Стабилизированные композиции для местного применения, содержащие микрокапсулы с ядром и оболочкой
CL2007003154A1 (es) Compuestos derivados de pirazolina; composicion farmaceutica que comprende a los compuestos; y uso para tratar afecciones cardiovasculares, renales, hepaticas y vasculares entre otras.
ES2501595T3 (es) Plancha litográfica de aluminio
CL2007003644A1 (es) Composicion antiparasitaria que comprende un compuesto derivado de pirazol sustituido y un segundo agente antiparasitario; kit que la comprende; y uso para tratar una infestacion parasitaria.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CY1112122T1 (el) Συνθεση σφαιριδιου λιποϊκου οξεος
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
GT200600040A (es) Nueva forma de sal de un agonista de dopamina
CR20120521A (es) Combinaciones de principios activos
ES2484068B1 (es) Una composición farmacéutica que contiene ketamina y amitriptilina
AR048167A1 (es) Suplemento dietetico con cantidades estequiometricamente especificas de citrato de potasio y magnesio
ATE515558T1 (de) Schattierungszusammensetzung
CL2013001153A1 (es) Compuestos derivados de carboxilato de fenilcetona y sus sales; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de un trastorno hematologico, una enfermedad inflamatoria, un trastorno renal o una disfuncion de organos relacionada con fibrosis.